Sheng-Hua Wu1, P-Y Liao, L Dong, Z-Q Chen. 1. Department of Pediatrics, Central Laboratory, the First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing, Jiangsu 210029, People's Republic of China.
Abstract
OBJECTIVE AND DESIGN: We examine whether lipoxin A(4) (LXA(4)) inhibits production of interleukins (ILs) in endothelial cells and what signal pathway might participate in the actions of LXA(4). METHODS: Cultured pulmonary microvascular endothelial cells (PMVEC) were treated with lipopolysaccharide (LPS), with or without preincubation with LXA(4). RESULTS: The results showed that LPS induced production of IL-1beta, IL-6 and IL-8 in rat PMVEC, upregulated the expressions of myeloid differentiation factor 88 (MyD88), phosphorylated p38 and p42/44 mitogen-activated protein kinase (MAPK), phosphorylated phosphoinositide 3-kinase (PI3-K), DNA-binding activities of nuclear factor-kappa B (NF-kappaB) and activator protein-1(AP-1). The blockade of p38 MAPK, p42/44 MAPK, PI3-K, NF-kappaB or AP-1 partially inhibited production of IL-1beta, IL-6 and IL-8 stimulated by LPS, respectively. LXA(4) significantly inhibited LPS-stimulated secretion of protein and expressions of mRNA of IL-1beta, IL-6 and IL-8, activation of p38 MAPK, p42/44 MAPK, PI3-K, NF-kappaB and AP-1 but not MyD88 in PMVEC. CONCLUSIONS: LXA(4) inhibits synthesis of IL-1beta, IL-6 and IL-8 in PMVEC and this antagonism is related to PI3-K, p38 and p42/44 MAPK, NF-kappaB and AP-1 pathway-dependent signal transduction.
OBJECTIVE AND DESIGN: We examine whether lipoxin A(4) (LXA(4)) inhibits production of interleukins (ILs) in endothelial cells and what signal pathway might participate in the actions of LXA(4). METHODS: Cultured pulmonary microvascular endothelial cells (PMVEC) were treated with lipopolysaccharide (LPS), with or without preincubation with LXA(4). RESULTS: The results showed that LPS induced production of IL-1beta, IL-6 and IL-8 in rat PMVEC, upregulated the expressions of myeloid differentiation factor 88 (MyD88), phosphorylated p38 and p42/44 mitogen-activated protein kinase (MAPK), phosphorylated phosphoinositide 3-kinase (PI3-K), DNA-binding activities of nuclear factor-kappa B (NF-kappaB) and activator protein-1(AP-1). The blockade of p38 MAPK, p42/44 MAPK, PI3-K, NF-kappaB or AP-1 partially inhibited production of IL-1beta, IL-6 and IL-8 stimulated by LPS, respectively. LXA(4) significantly inhibited LPS-stimulated secretion of protein and expressions of mRNA of IL-1beta, IL-6 and IL-8, activation of p38 MAPK, p42/44 MAPK, PI3-K, NF-kappaB and AP-1 but not MyD88 in PMVEC. CONCLUSIONS:LXA(4) inhibits synthesis of IL-1beta, IL-6 and IL-8 in PMVEC and this antagonism is related to PI3-K, p38 and p42/44 MAPK, NF-kappaB and AP-1 pathway-dependent signal transduction.
Authors: Christine D Palmer; Christy J Mancuso; Jerrold P Weiss; Charles N Serhan; Eva C Guinan; Ofer Levy Journal: J Leukoc Biol Date: 2011-06-07 Impact factor: 4.962
Authors: Richard D Ye; François Boulay; Ji Ming Wang; Claes Dahlgren; Craig Gerard; Marc Parmentier; Charles N Serhan; Philip M Murphy Journal: Pharmacol Rev Date: 2009-06-04 Impact factor: 25.468
Authors: Brian T Steffen; Lyn M Steffen; Shuang Liang; Russell Tracy; Nancy Swords Jenny; Michael Y Tsai Journal: Br J Nutr Date: 2013-04-03 Impact factor: 3.718
Authors: Linsay J Macdonald; Sheila C Boddy; Fiona C Denison; Kurt J Sales; Henry N Jabbour Journal: Reproduction Date: 2011-05-09 Impact factor: 3.906